GILEAD SCIENCES - Dusseldorf Stock Exchang (GIS DU) stock market data APIs
€101.6376
0.25(0.2%)
as of October 14, 2025
Try our APIs with
free plan!
GILEAD SCIENCES - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GIS.DU.
Prev. Close
101.6376
Open
101.8865
High
101.6376
Low
101.8865
52 wk Range
77.2176-108.8846
Market Cap
78 028 M
Dividends (Yield)
0.0273
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GILEAD SCIENCES - Dusseldorf Stock Exchang data using free add-ons & libraries
Get GILEAD SCIENCES - Dusseldorf Stock Exchang Fundamental Data
GILEAD SCIENCES - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get GILEAD SCIENCES - Dusseldorf Stock Exchang Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get GILEAD SCIENCES - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GILEAD SCIENCES - Dusseldorf Stock Exchang News
New
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
– Late-breaking Phase 3 ASCENT-03 Study Results Highlight Potential for Trodelvy® to Redefine First-Line Metastatic Triple-Negative Breast Cancer Treatment – – New EDGE-Gastric Overall Surviva...
How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline
In recent days, Gilead Sciences announced a series of developments, including settlement agreements that extend Biktarvy's U.S. exclusivity to 2036 and updates on innovative therapies in HIV preventio...
How the Story Behind Gilead Is Evolving in Light of Key Analyst and Industry Updates
Gilead Sciences has seen a slight increase in its consensus analyst price target, rising from $124.91 to $126.31. This subtle uptick reflects an improved outlook for Gilead's core businesses as analys...
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
Resurfaced tensions between the U.S. and China caught the market off guard in Friday’s trading session, with the S&P 500 and Nasdaq falling over 2% on news that President Trump plans to impose an ad...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
